**How does an ectodomain of membrane-associated proteins stand upright and exert robust**
**signal?**

**Author Information**

**Swetha Lankipalli[1,2] and Udupi A. Ramagopal[1] \***

[1]Biological Sciences Division, Poornaprajna Institute of Scientific Research (PPISR),
Bidalur post, Devanahalli, Bengaluru, 562164, India

[2]Manipal Academy of Higher Education, Manipal, Karnataka, India-576104

*To whom correspondence may be addressed:

Udupi A. Ramagopal, Biological Sciences Division, Poornaprajna Institute of Scientific
Research (PPISR), Bidalur post, Devanahalli, Bengaluru, 562164, India
Ph.: +91 9900810182; E-mail: ramagopal.udupi@gmail.com

**Abbreviations:**

IgV- Immunoglobulin V-type domain; IgC- Immunoglobulin C-type domain

**Keywords:** Ectodomain; 'upright' orientation, protein clustering; one-dimensional array;
nanoclusters, spurious signaling; non-signaling resting state.

**Abstract:**

Even after decades of research, a comprehensive mechanism that elucidates the underpinnings of

signaling through the cell membrane is still elusive. Here, we address a simple question- "how

does the ectodomain of a membrane-associated protein consisting of multiple domains and

connected by flexible linkers stand 'upright' on the membrane?". Our analysis based on large

amount of available structural and functional data, looking for a pattern of association of these

molecules in the crystal structures and with the concept that 'random things seldom repeat' lead to

a surprisingly interesting and consistent observation that (1) the weak *cis*-interaction mediated

symmetric oligomerization of signaling molecules not only support their 'upright' orientation but

often bury their ligand-binding surface to avoid spurious signaling (2) the linkers connecting the

domains are probably not flexible as presumed. This analysis provides a model for pre-liganded

receptor supramolecular organization that resolves some of the mysteries unanswered by

hypothesis such as 'lipid-rafts' and 'fence and pickets. With CD4, pMHCII, CD2 and TNFR1 as

examples, we show that the observed *cis*-association of molecules also correlate well with their

functional role. Further, our analysis reconciles the long-standing controversies related to these

molecules and appear to be generic enough to be applied to other signaling molecules.

.

**Introduction:** Membrane-associated proteins constitute ~50% of the total cell-surface volume and play a critical role in the detection and integration of extracellular mechanical, physical and chemical stimuli and hence play a vital role in cell-cell recognition and communication[1]. Its organization is of interest for over a century. Nano, meso, and micro-clusters of membrane-associated proteins have been revealed by super-resolution microscopy(**see, supplementary Information-section 2.1**) and now can be quantitatively investigated[2]. It is also known that on the cell membrane, these proteins cluster and organize/reorganize depending on the functional context such as polarity, adhesion, immune, and synaptic functions [3-5]. However, what is not clear is; how do they achieve this compartmentalization and how the clustering state imparts the ability to perform the accurate and reproducible function? Models such as 'lipid rafts' [6] molecular crowding [7] and 'fences and pickets' have been proposed [8] to explain the clustering phenomenon. Unfortunately, the diversity of these clusters can't be explained satisfactorily by any of these models [5, 9-15]. Further, the control of association of these proteins with large sequence and architectural diversity, by either lipid-rafts or by the intracellular cytoskeleton network is difficult to perceive. For example, most clusters are homotypic [16, 17] which requires a mechanism that can segregate proteins based on their identity. Recent reports propose that the ability of these proteins to cluster with each other (homo or hetero depending on the cluster) is inherent in them and is mediated by weak protein-protein interactions[9, 18, 19]. However, the physicochemical signatures governing the sorting of these molecules in to clusters of different sizes and architecture, with the ability to reorganize and perform reproducible and accurate function avoiding spurious signaling remain unanswered[4].

Interestingly, even a much fundamental question, how cell-surface proteins position themselves 'upright' on the membrane prior to their interaction with a cognate partner on the opposing cell is a mystery. The ectodomains of these proteins vary in size, architecture, and most of them consist of multiple domains connected by linkers (Fig. 1). Further, they are membrane-tethered via an extended extracellular juxtamembrane linker (hereafter called as EJ-linker) which is purported to be flexible. For these membrane proteins to exert reproducible organization and function, they are expected to be robust and at the same time pliable to respond to weak cues and transform them into robust signals across the membrane. It is intriguing to know, how these considerably large cell surface molecules connected by multiple interdomain linkers maintain appropriate orientation and perform an accurate function. Further, flexible linkers can increase the conformational entropy of

a protein on the cell membrane, and hence it is likely that such molecules on the crowded
membrane are prone to tangle with each other forming aggregates that can never respond to a
specific signal.

In most of these cases, the extracellular domains distal to the membrane are the ones that interact
with their cognate partners on the opposing cell. Hence, these molecules are expected to stand
'upright' on the cell surface and position the membrane-distal domain(s) in an optimal orientation
on the cell surface to ensure efficient function. Further, the elegant 'kinetic segregation' model
that explains the segregation of molecules in the cell-cell contact during T-cell signaling requires

that the distance spanned by each
molecule from the membrane is
proportional to the effective length of the
molecule [20]. Although, current
techniques such as super-resolution
microscopy [21], single-molecule
tracking [22, 23]and other allied
techniques have revolutionized the way
we look at the biological systems[24],
unfortunately, even the improved
resolution does not provide a
comprehensive mechanism for
controlling the association and function
of these molecules[25].

**Fig.1** Representative structures of diverse type-I membrane associated proteins. The naming convention used are also diverse- they are named as $D_1$ to $D_n$ (Domain 1 to Domain 'n'), EC1 to $EC_n$ (ectodomain 1 to 'n'), CRD1 (Cysteine rich domain 1 to 'n'), where is 'n' is an integer and also sometimes they are named based on their fold such as IgV, $IgC_1$, $IgC_2$, etc. The multidomain proteins with a stalk like EJ-linker (extracellular juxtamembrane linker) are tethered to the membrane by a single pass transmembrane helix. The N terminus is at the membrane distal end on the extracellular side while the C terminus is on the cytoplasmic side of each protein.

We asked the question, whether the
packing analysis (association in the
crystals) of pool of available crystal
structures provide any clue on preferential and organized association and whether such an
association (though weak) manifests itself in the crystal, revealing physiologically relevant pre-
liganded *cis* interactions? In fact, the insights that can be gained from crystal structure analysis in
the case of adhesion molecules has been extensively discussed by Honig. B and Shapiro. L[26]
**(For more such examples see, supplementary Information-section 2.2)** Since the crystal

formation requires epitope(s) of association[27] on the surface of each molecule that can support

the formation of 3D lattice, in the absence of any preferred interaction, these molecules are

expected to have an infinite modes of self-association. In contrast, if the ectodomains of these

proteins on the same cell have physiologically relevant pre-liganded association preference (*cis*

association), although weak-to-be-detected in solution, we pondered whether any such preferred

association can be observed in the crystals from the pool of available crystal structures of these

receptors. The proteins described here are those that fit into the following criteria (1) ectodomains

that are known to be monomers in solution (or oligomers weak-to-be-detectable in solution) (2)

multiple crystal structures have been determined for the complete ectodomain of the same

molecule either from the same organism or from different organisms. This criterion was set to

make sure that the observed association in the crystal is not an accidental observation and those

that repeat might have some significance (random things seldom repeat) (3) since our question is

regarding the pre-liganded association, to eliminate the effect of cognate binding partners, only

apo structures were considered first and later they were compared with the complex structures

containing cognate partner (4) we did not consider homomers such as cadherins and other cell-

adhesion molecules as they tend to organize with stronger (detectable) *trans*  and *cis* interactions

in the crystals. The *cis* association observed in the crystals of adhesion molecules are result of post

*trans* association and hence may not represent *cis* association of these molecules on the individual

cell.

Based on our analysis, we propose that the cryptic *cis*-oligomerization and supramolecular

association of rigid ectodomains together with conformational entropy constrained by membrane

tethering helps them to stand 'upright' on the cell surface. More interestingly, these weak

oligomers often hide their ligand-binding surface to avoid spurious signaling and can further

associate into higher-ordered arrays. Importantly, this analysis reconciles some of the contradicting

observations pertinent to T-cell signaling mediated by MHCII-TCR-CD4 and other molecules such

as CD2 and TNFRs involved in immune signaling.

**Results and discussion:**

**Interdomain flexibility and the role of EJ-linker:** To understand the interdomain flexibility of

multi-domain cell-surface receptors, the crystal structures of several of these molecules present on

immune cells were analysed. The structure of receptors containing 2-3 Ig domains, such as CD2,

NTB-A, PD-L1, PD-L2, B7-1, Nectin1, Nectin2, Nectin3 and so on reveal that the interdomain

hydrophobic interactions help in maintaining a stable relative orientation [28-33]. Similarly, in the

case of larger molecules such as CD4, cadherins, ephrins, CD45, CD22 and so on, it has been

observed that the structure of truncated proteins with few domains superposes well with the

complete ectodomain structures of these proteins**(Fig. S1)** [34-38]. In molecules such as cadherins,

CEACAM-1, Syntaxin, SNAP25 and so on, the interdomain stabilization is mediated by calcium

ions[39-41] **(supplementary information- section 3.1)**. Also, in most of these proteins, solution

studies confirm that the structures observed in the crystals are highly similar to their conformation

in solution [36, 40]. The above analysis suggests that these receptors containing multiple domains

connected by linkers are rigid or posses' minimal inter-domain flexibility. The observed

interdomain stability of the ectodomain cannot be a complete answer for their ability to stand

'upright' as they are tethered to a jelly-like membrane via an EJ-linker which is presumed to be

**Table-1** Proline rich sequences of extracellular juxtamembrane linker(EJ-linker) of selected type-I membrane associated proteins and overall percentage of hydrophobic residues.

| Uniprot ID | Protein name | No. of amino acids (sequence position) | EJ-linker-sequence | % of prolines in the linker sequence | total % of hydrophobic aa in the linker sequence (including proline) |
|---|---|---|---|---|---|
| | | | | | |
| P42081 | hB7-2 | 11 (237-247) | EDPQPPPDHIP | 45.45 | 54.4 |
| P01730 | hCD4 | 8 (389-396) | TWSTPVQP | 25 | 50 |
| P16410 | hCTLA-4 | 11(154-164) | PEPCPDSDFLL | 27.27 | 54.54 |
| Q9NZQ7 | hPD-L1 | 9 (230-238) | PLAHPPNER | 33.33 | 55.55 |
| Q9BQ51 | hPD-L2 | 11 (210-220) | QSQMEPRTHPT | 18.18 | 27.27 |
| P19438 | hTNR1A(hTNFR1) | 15 (197-211) | PQIENVKGTEDSGTT | 6.66 | 33.33 |
| P20333 | hTNR1B (hTNR2) | 56 (202-257) | STSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGD | 21.42 | 50 |
| P19022 | N-cadherin | 11 (715-725) | IVGAGLGTGAI | 0 | 90.90 |
| P12830 | E-cadherin | 12 (698-710) | QPVEAGLQIPAI | 16.66 | 75 |
| Q9NQS3 | hNectin-3 | 49 (357-405) | DPPTTTTLQPTIQWHPSTADIEDLATEPKKLPFPLSTLATIKDDTIATI | 14.28 | 46.93 |
| Q15223 | hNectin-1 | 22 (335-356) | EFPYTPSPPEHGRRAGPVPTAI | 27.27 | 59.09 |
| Q92692 | hNectin-2 | 15 (346-360) | VRETPNTAGAGATGG | 6.66 | 60 |
| Q15116 | hPD-1 | 25 (146-170) | ERRAEVPTAHPSPSPRPAGQFQTLV | 20.00 | 52.00 |
| Q495A1 | hTIGIT | 14 (129-142) | SSVAEHGARFQIPL | 7.14 | 57.14 |
| P43489 | hOX-40 | 47 (168-214) | DRDPPATQPQETQGPPARPITVQPTEAWPRTSQGPSTRPVEVPGGRA | 23.40 | 51.06 |
| P36941 | TNR3(TNFR3) | 16 (212-227) | NPLEPLPPEMSGTMLM | 25 | 68.75 |
| P10747 | hCD28 | 16 (138-153) | KHLCPSPLFPGPSKPF | 31.25 | 62.50 |

flexible. Since the EJ-linker is in the aqueous environment just outside the cell surface, if flexible,

it is expected to contain more of hydrophilic residues. Our analysis suggests that it is not always

true. For example, in some of the key molecules involved in immune function, the sequence of the

EJ-linker contains close to 50% hydrophobic residues and sometimes rich in conformation

constraining residues like proline, together with aromatic residues **(Table-1).** Such sequences are

expected to be rigid and being substantially hydrophobic, their existence in the aqueous

extracellular region requires burial of these hydrophobic residues.

This raises the question of whether they are flexible as generally presumed or such linkers from

adjacent molecules on the cell membrane can associate with each other through their hydrophobic

residues, stabilizing well-defined oligomers and/or have the ability to get involved in energetically

similar but different oligomerization states? Unfortunately, EJ-linker is the most neglected part of

all the studies directed towards structural characterization, oligomerization, and clustering. In most

such studies involving cell-surface molecules, manipulations are done on the ectodomain

(excluding the EJ-linker) and/or on the intracellular domain. **(see supplementary information**

**section 3.2 for few specific examples)** These observations suggest that the inclusion of the EJ-

linker region is important in studies involving, oligomerization and signaling. However, there are

few examples, where EJ-linker oligomerization has been shown to impact the signalling ability of

receptors. In the following section, we briefly discuss few examples where importance of

juxtamembrane linker has been observed.

Tropomyosin receptor kinases (Trks- TrkA, TrkB and TrkC) which also belongs to the family of

receptor tyrosine kinases (RTKs) are important receptors in the development of nervous system

and are activated by different nerve growth factors (NGFs). The architecture of a typical Trk has

an extracellular domain with a membrane distal Leucine rich domain (D1), followed by two

cysteine rich domains (D2-D3) and two Ig like domains (D4 and D5). The D5 domain is followed

by an extra-cellular juxtamembrane linker (EJ-linker), a transmembrane domain and a cytoplasmic

kinase domain. Dimeric ligand (NGF) binds to the D5 domain of Trk and like other RTKs, Trks

were initially considered to form ligand induced dimers. In contrast, many biochemical studies

such as chemical cross-linking experiments, protein fragment complementation assays and crystal

studies of the kinase domain have shown that Trks could exist as pre-formed inactive dimers[42].

Also, the study has shown that the pre-formed inactive dimers are mediated by interactions of EJ-

linker and by deletion of EJ-linker, it was shown that EJ-linker acted as an inhibitory motif for the

formation of active dimer. The binding of ligand to the D5 domain was presumed to over-ride the

inhibitory interactions of EJ-liker leading to ligand induced active dimer formation. Further,

Franco et.al., have supported the role of EJ-linker in the pre-liganded inactive dimer by mutation

studies, MD simulations and have also elucidated the dimerization of transmembrane domain by

NMR studies concluding that EJ-linker and transmembrane domain are involved in the pre-

liganded inactive dimerization of Trks[43]. Similarly, EGFR is one of the well-studied receptor

tyrosine kinase. Replacement of juxtamembrane-linker with an unstructured $(GGS)_{10}$ sequence

abolished phosphorylation of all the tyrosine residues, affected receptor dimerization and ligand

binding capability. There are several similar studies showing the effect of EJ-linker on receptor

functions, particularly on the receptor tyrosine kinases[44]. In the case of T-cell co-inhibitory

receptor CTLA-4 (cytotoxic T lymphocyte-associated protein-4). It is a CD28 family member and

the ligand binding domain of CTLA-4 is a weak homodimer[45]. Various studies have shown that

CTLA-4 forms a stable dimer only in the presence of EJ-linker (with sequence [119]Pro-Glu-Pro-

Cys-Pro-Asp[124] which is also conserved in all CD28 family members). Consistent with this, in the

structure of CTLA-4 that includes proline rich EJ-linker, it has been observed that the linker

together with few hydrophobic residues results in a stable dimer which is further stabilized by a

disulfide bond between the two protomers of the dimer[46].

Apart from the putative role of EJ-linker and limited inter-domain flexibility of ectodomain, the

preferential association of ectodomains of adjacent identical proteins (*cis*-interactions) appears to

be important for 'upright' (or appropriate) orientation and robust signaling. In the following

section, we present few cases, where ectodomain of these receptors are known to be monomers in

solution (or more accurately, possess undetectable oligomerization potential), but consistently

exist as multimers in the crystal, maintaining similar physiologically relevant association. Other

than the criteria used for the selection of molecules discussed above, we restricted ourselves to

immune molecules, the field of our expertise, where we can effectively correlate their function to

the observed association preference.

**1D array of CD4**: The CD4 is a key co-receptor on the T-cells that interact with peptide-loaded

major histocompatibility complex-II (pMHCII) on the antigen-presenting cells (APCs) and

contributes to signal transduction through its cytoplasmic tail by interacting with lymphocyte

kinase (Lck) [47]. The ectodomain of hCD4 consists of four Ig domains (named D1 to D4), where

the membrane distal domain (D1) is shown to interact with pMHCII[48]. Although there is no

clear indication of dimerization of CD4 ectodomain in solution[49], the dimeric association of

CD4, involving the membrane-proximal D4 domain has been observed in three different isoforms

of CD4(D1-D4) crystals (PDB-entry: 1WIQ, 1WIP, 1WIO; **Fig. 2A**)[34]. The description of the

structure in the author's own words is very interesting "*the D4-D4 associated dimers are butterfly-*

*shaped in profile, with D1-D3 as 'wings', D4 pair as 'torso' and C termini as 'legs', as if perching*

*on the hypothetical membrane surface perpendicular to the dyad axis*", which clearly depicts the

dimeric 'upright' orientation of CD4 on the cell membrane. While analytical ultracentrifugation

and light scattering studies did not support CD4 oligomerization, crosslinking, mutational and

immunoprecipitation studies confirmed the role of the D4 domain in CD4 dimerization[34, 50]

**Fig.2 Structural details of ectodomain of CD4 (D1-D4) (A)** Cartoon representation of dimeric CD4, the monomers coloured in cyan and orange associate via their membrane proximal D4 domains and the D4 domains interact with the membrane placing the D1-D3 domains distal to the cell surface. **(B)** Superposition of three different crystal structures of CD4 (ribbons) (PDB entries: 1WIP, 1WIQ, 1WIO) highlighting the exactly similar D4-D4 mediated dimeric association of two protomers (maximum $C_\alpha$ RMSD of ~1.2Å). **(C)** packing analysis of the three different structures of CD4 (surface representation) reveals a formation of identical 1D array of CD4 homodimers due to D4-D4 interaction and D1-D1 interaction conserved in all the three structures. The D1-D1 interface (shaded in dark blue), partially overlaps with pMHCII binding site (shaded in yellow) precluding its binding to MHCII in non-*signaling* resting state and hence appear to avoid spurious signaling.

Contrary to this observation, there is a considerable argument in favour of CD4 dimerization
through the D1 domain[51] and independent experiments involving mutations on either D1 or D4
domains resulted in impaired dimerization[50, 52, 53]. In fact, our packing analysis of these
molecules in the crystals of complete ectodomain of CD4 reveals that the pairing of D4-D4
domains together with the pairing of D1-D1 domains form a zigzagged 1D array of CD4 molecules
**(Fig. 2C)** (similar to a portable zigzagged display panel). Consistent with this observation, at
higher concentrations (5mg/ml) analytical ultracentrifugation studies revealed a non-ideal
behavior of CD4 in solution[34]. Further, we also note that the D1-D1 domain interaction observed
in the above structures is canonical which is generally observed in most receptor: ligand interaction
involving IgV domains. Moreover, the same mode of interaction is conserved in all the six different
crystal structures containing only D1-D2 domains, **(Fig. S2)**, and is in line with mutation studies
mentioned above.

Therefore, (1) the conservation of similar association of D1 domains in all the nine crystal
structures, (2) their canonical association (3) the functional data that corroborates well with
observed D1 and D4 dimers, suggest the probable physiological role of dimerization of CD4 at
both ends.  Moreover, the structures of all the apo CD4 monomers, truncated structures, and the
one that is observed in the MHCII:TCR:CD4 ternary complex[54] superpose well with each other,
suggesting the elongated CD4 ectodomain is rigid. Hence, it appears that the rigid structure of CD4
ectodomain together with zigzagged 1D array, (a supramolecular organization of CD4) supports
the erect orientation of CD4 molecules on the cell surface. The most interesting observation that
emerged out of this analysis is that the membrane distal D1-D1 interface that appears to support
the 'upright' orientation of CD4 molecules on the cell surface is also used for pMHCII binding,
which closes itself in supramolecular organization. Hence, the formation of pre-liganded 1D array
and consequent closing of pMHCII binding site on D1, not only helps its 'upright' orientation on
the cell surface but also appear to avoid spurious interaction with the pMHCII molecules present
on the opposing APCs during the screening of peptide by TCR. Consistent with these observations,
in a study aimed at determining the association between HIV viral entry and CD4 receptor
dimerization, both D1 mutants and D4 mutants were used.  Here they report the increased HIV
viral entry efficiency in the case of both the mutants compared to wt CD4. The reduced
dimerization observed in both D1 mutants, as well as D4 mutants, suggested that the two different
CD4 dimeric forms (D1 dimer as well as D4 dimer) co-exist on the cell surface[52]. As explained

in the main-text, closing of D1 domain (that interacts with MHC-II as well as gp120 of HIV ) is

essential for avoiding spurious signaling. The continous array of CD4 shown in our analysis is

prone to be disturbed by either of the mutants and hence, disturbance of dimerization probably

results in uncontrolled interaction D1 domain with gp120 making its entry efficient.

**New model for pMHC-TCR-CD4 mediated signaling**: The pMHCII-TCR-CD4 complex is

central to immunological synapse formation. Although signaling through pMHCII with TCR and

CD4 is important, the mechanism by which such an accurate process is achieved is still enigmatic.

Recognition of pMHCII present on the APCs by TCR on T-helper cells is known to trigger the

interaction of co-receptor CD4 (present on T-helper cells) with pMHCII. pMHCII is a heterodimer

consisting of two chains named α and β, with the peptide-binding groove crafted from residues

involving both the chains. The first report describing the two crystal structures of pMHCII (HLA-

DR1 with antigenic peptide) from the human B-cell membrane describes a dimer of heterodimers

(later termed as superdimers) in both the crystal forms(PDB entries: 1DLH, 1AQD)[55]. The

parallel association of two heterodimers brings all the four C-termini in one direction with both

the peptide binding groves facing in the opposite direction that supports the presentation of bound

peptides in an orientation appropriate for recognition by TCRs on juxtaposed T-helper cells **(Fig.**

**3A).** Here, facing of the C-terminal end of all the four molecules in one direction and consequent

tethering to the membrane at four different points in proximity appears to stabilize the 'upright'

orientation of MHCII. The authors also propose that the superdimer might bind to CD4 coreceptor

with increased affinity and hence initiate TCR mediated signaling. Subsequent determination of

several crystal structures of pMHCII variants (HLA-DR1; PDB-entries: 1KG0, 4I5B, 1AQD)

including HLA-DR1 in complex with superantigen *Staphylococcus aureus* enterotoxin B (PDB

entry: 1SEB) and HLA-DR3 (PDB entry: 1A6A) revealed a similar association of dimer of αβ

heterodimers. This superdimer is expected to be very weak as the interface is formed by

discontinuous stretches of polar and charged residues with very few hydrophobic interactions [55].

This might probably be the reason for the lack of any evidence of such superdimer in solution as

measured by hydrodynamic radii and other techniques[56, 57]. However, chemical crosslinking

studies and immunoprecipitation of pMHCII dimers (I-E$^k$) from B-cell[58, 59] also supported the

"superdimer mediated T-cell activation" hypothesis. Later, the structure determination of complete

ectodomain of CD4 and the observation that the CD4 also exists as a dimer (discussed in the

previous section on CD4), triggered interest in investigations on the possibility of dimeric CD4

and pMHCII superdimer mediated T-cell signaling[53].

Interestingly, the superdimer which was observed in most of the pMHCII variant crystal structures

was not seen in any of the crystal structures of pMHCII in complex with TCR (PDB-entries: 1FYT,

2ICW, 2WBJ, 2XN9, 1ZGL, IJ8H, etc.,), in the structures of pMHCII in complex with CD4(D1-

D2, PDB entries: 1JL4, 3S4S, 3S5L, etc.,) and also in the ternary complex structure of pMHCII-

TCR and CD4 (PDB entry: 3T0E)[54]. The structures of pMHCII in complex with CD4 (D1-D2)

revealed that the CD4 binding region is in the interface formed by $\alpha_2$ and $\beta_2$ domains on pMHCII

which is completely hidden in the pMHCII superdimer interface[48]. The authors also propose a

V-shaped model for the TCR-MHC-CD4 ternary complex which later matched with the crystal

structure of the ternary complex (PDB entry: 3T0E)[54], with complete ectodomain of CD4. With

the absence of superdimeric structures of pMHCII in complex with TCR and/or CD4, the earlier

models which emphasized pMHCII superdimer as a functional entity lost their relevance and it is

now established that TCR-pMHCII-CD4 is a complex containing a single unit of each protein.

**Fig.3 A new model of pMHCII:TCR:CD4** *signaling*: **(A)** Cartoon representation of pMHC-II superdimer observed in different crystal structures depicting dimer of heterodimer formed by an α and β chain. The C-termini of all the four chains (2α and 2β) face in the same direction as if emerging from the same cell. Thus, it is anchored at four points stabilising the *'upright'* orientation **(B)** Surface representation of the pMHCII superdimer hiding the CD4 binding site (shaded in red) in the dimer interface **(C)** TCR (magenta):pMHCII (green) complex reveals that pMHCII exists as heterodimer but not as superdimer in the complex. Note that the disassembly of superdimer into heterodimer exposes the CD4 binding site (shaded in red) on MHC. **(D)** Ternary complex structure of pMHC:TCR:CD4(cyan) (PDB entry: 3T0E) showing simultaneous interaction of TCR and monomeric CD4 with pMHCII heterodimer. CD4 interacts with MHCII via its D1 domain.

Unfortunately, the importance of such an elegant pMHCII superdimer which was observed in
many crystal-structures of pMHC and proven to be present on the cell-surface by other studies
[59]was comfortably forgotten thereafter. Based on the observations made from all the currently
available crystal structures of pMHCII superdimers, pMHC-TCR structures (>25 structures),
pMHC-CD4(D1-D2), and the ternary complex structures of TCR-pMHC-CD4, we provide a
model that reconciles all the experimental observations and highlight the importance of pMHCII
superdimer. As observed in the pMHCII structures, the superdimer might be the native state before
binding to TCR which precludes CD4 binding, as the CD4 binding site is buried in the superdimer
interface **(Fig. 3B).** When the MHCII loaded with antigenic peptide interacts with specific TCR
and with an appropriate strength, the resulting mechanoforce might dislodge the weak pMHCII
superdimer, exposing the CD4 binding site **(Fig. 3C).** As mentioned above, this is consistent with
all the TCR: pMHCII crystal structures, where monomeric TCR is observed to interact with
pMHCII heterodimer (and not the superdimer) with exposed CD4 binding site **(Fig. 3C)**.
Subsequently, the binding of monomeric CD4 to pMHC-TCR complex forms the V-shaped arch
**(Fig. 3D)** as observed in the ternary complex structures and probably results in downstream
signaling initiated through Lck. Thus, it appears that pMHCII is an obligate superdimer that hides
its CD4 biding site and avoids CD4 interaction prior to recognition of specific antigenic peptide
on it by TCR. It should be noted that the hiding of the binding partner interface and utilization of
the same interface to oligomerize and stand 'upright' on the cell surface, is a common strategy
used by both CD4 (as described in the previous section) and pMHCII. This way, the superdimer
of pMHCII stabilizes the 'upright' orientation for an efficient presentation of the antigenic peptide
to T-cell. Therefore, the repeated observation of superdimers of pMHCII appears to be
physiologically relevant, however, the presumption that pMHCII superdimer is the signaling unit
led to models that did not explain subsequent findings. Similarly, in the case of CD4, the
investigations supporting both D4-D4 pairs as well as D1-D1 pair appears to be correct and
together with several structures, they appear to represent the physiologically relevant pre-liganded
association.

Another important observation that emerged out of this analysis is that, in the ternary complex of
CD4-pMHCII-TCR, the overall structure of monomeric CD4 (D1-D4 domains) is very similar to
the apo structure of CD4 (RMSD ~1.8Å) **(Fig. S3-A)** [54]. Our analysis indicates that the D4
domain of CD4 which appears to interact with the membrane along its elongated surface as

described in the apo structure, upon interaction with pMHCII moves away from the membrane,

orienting itself almost perpendicular to the membrane surface **(Fig. S3-B)**. Although the overall

structure of CD4 is unchanged, the reorientation of the D4 domain with respect to the membrane

and the EJ-linker appears to provide sufficient length to reach the CD4 binding site on pMHCII

present on the opposing cell. This reorientation due to interaction with pMHCII probably exerts

sufficient machanoforce that dislodges the D4-D4 dimer consequently disturbing the relative

orientation of its intracellular domains. This change in the intracellular part of CD4 might also

help its association with Lck. Concomitant with this, it has been proposed in the crystal structure

of the ternary complex of CD4-pMHCII-TCR, the arc-shaped structure also brings the C-terminal

D4 domain of CD4 closer to the TCR:CD3 assembly.

**1D array of CD2**: CD2 is one of the first few structurally investigated cell surface molecules

implicated in immune function and

it is known to be present in close

proximity to TCR:pMHC:CD4

complex on the cell surface [31, 60].

It is a cell adhesion molecule,

expressed on T-lymphocytes.

Human and rat CD2 are shown to

interact with their cognate ligands

CD58(LFA-3)[61] and CD48

respectively[62], all of which

belong to CD2 family. The

ectodomain of CD2 consists of a

membrane distal IgV domain followed

by membrane-proximal IgC domain.

Overall structures of human (hCD2;

PDB-entry: 1HNF) and rat CD2

(rCD2; PDB-Entry: 1HNG) are very

similar **(Fig. S4)** with average $C_\alpha$

**Fig.4 Comparative analysis of crystal structures of rCD2(PDB entry: 1HNG), hCD2 (PDB entry: 1HNF) and hCD2:CD58 complex (PDB entry: 1QA9).** The dimeric associations observed in different crystals are similar and the homodimeric interactions of rCD2(magenta) and hCD2 (green) mimics the heterodimeric interaction of hCD2 with its cognate partner, CD58(blue) supporting the proposition that heterophilic interactions in CD2 family evolved from a homophilic precursor. hCD2:hCD58 structure shown here is obtained by superposition of full length hCD2 and full length CD58 on to respective proteins in CD2:CD58 complex structure containing only IgV domains (PDB entry: 1QA9)

RMSD of 1.3Å, which confirms the relative rigid orientation of IgV and IgC domains [31, 60].

Interestingly, although CD2 is known to be a monomer in solution[63, 64], each molecule seen in

both the structures is involved in the exactly similar dimeric association of IgV domains identical
to that observed in canonical homophilic and heterophilic interactions involving IgV domains of
immune receptors[65] and mimics the interaction of CD2 with its cognate partner CD58/ CD48
**(Fig. 4)** [31]. The superposition of rCD2 and hCD2 canonical dimers reveals that the two dimers
are very similar **(Fig. S4).** The dimers can be depicted as either *trans* or *cis*, since the association
satisfies both the forms **(Fig. S5-A) (See, supplementary information- section 4 for more**
**discussion and examples on *cis-trans* notion)**. Based on the observation that the genes for
CD58/CD48 and CD2 lie in proximity on chromosome-1[66, 67], it has been proposed that the
heterophilic interaction in this family might have evolved from a common homophilic
precursor[64], suggesting that the conservation of canonical homodimeric interaction observed in
both CD2 structures, is probably physiologically relevant. Further, another structure of hCD2
containing only IgV domain maintains a similar canonical front-face to front-face interaction **(Fig.**
**S4)**, even though the structure is domain-swapped (PDB entry: 1CDC)[68]. Maintenance of similar
and canonical interactions between IgV domains in all the three different crystal structures suggest
that the observed association, although very weak-to-be-detectable in the solution, appears to be
the preferred mode of association of CD2 prior to its interaction with cognate partner.

**Fig.5 Surface representation of one-dimensional array of hCD2 as observed in the crystal structure (PDB entry:1HNF).** Note that the dimer which appeared as '*trans*' as shown in Fig.4 can also be considered as '*cis*' and such *cis* dimers hide the CD58 binding site (shown as pink spheres) on CD2. The *'cis'* dimers further interact to form a one-dimensional array of molecules supporting each other in an *'upright'* orientation perpendicular to the membrane. The N linked glycans are shown in blue spheres. N-glycans (at N65) between the adjacent *'cis'* dimers act as fillers and the glycan at N117 which is close to the membrane might stabilise the *'upright'* orientation. The red arrows indicate EJ-linkers extending towards membrane.

366 Careful analysis of crystal packing of hCD2 molecules reveals that these molecules form a 1D
367 array along the crystallographic *z*-axis, which places the membrane-proximal IgC domain (hence

the EJ-linker) of all the molecules of the 1D array in the same direction as if they are emanating from the same cell **(Fig. 5)**. It is interesting to note that the N-glycosylation at Asn65(in the structure-1HNF) is located at the gap created between canonical CD2 dimers of this array and appears to act as a filler **(Fig. 5).** Conservation analysis reveals Asn65 is highly conserved (91%) across species **(Fig. 6).** In this array, the CD58 binding surface of CD2 is completely buried in the CD2 homodimeric interface. If the array seen in the crystal is reminiscent of pre-liganded state of CD2 molecules on the cell membrane prior to its interaction with CD58, then such an association with 'closed' ligand-binding surface might suffice the condition required for avoidance of spurious interactions and also provides support for 'upright' orientation of the molecules on the cell surface. Concomitant

**Fig.6 Sequence logo depicting the conservation of N-glycosylation sites in CD2 across species**: N65 and N117 boxed in blue dashed lines (numbering according to PDB structure 1HNF) are conserved by 91% and 86.4% respectively. While the glycan at N65 might act as a filler between the adjacent proteins of the 1D-array, the glycan at N117 lies close to the membrane and might have stabilising interactions with the membrane. The third glycan is at N126, also seen in the structure, but the site is only 27% conserved.

with this observation, single-molecule tracking of few raft-associated (Lck and LAT) and non-raft associated proteins (CD2 and CD45), which are known to be important in T-cell function, suggested an unexpectedly low diffusion coefficient for a non-raft associated protein CD2 (lowest among all the molecules studied)[69]. Here the assumption was that raft-associated protein should diffuse slowly compared to non-raft associated proteins. In this context, the 1D association appears to be physiological and provides an explanation for unusual low diffusion coefficient observed for the non-raft associated CD2.

**1D array of TNFR1:** Tumour Necrosis Factor (TNF) is a cytokine which interacts with its receptors TNFR1 and TNFR2. Currently, several TNF family members (29 receptors and 19 ligands in humans) have been identified and are known to play an important role in the immune response. While the ligands are type-II membrane proteins with trimeric extracellular domain and include both membrane-tethered as well as soluble versions, the receptors are type-I membrane proteins mostly membrane-bound with the exception of soluble decoy receptors. Also, receptors

are elongated structures with 3-4 cysteine-rich domains (CRDs) and some of them interact with

multiple ligands[70]. Further, the 'ligand-induced trimerization' model suggests that the receptors

get trimerized only in the presence of trimeric ligand, where the inter-digitization of monomeric

receptors in the groves of trimeric ligands have been observed[71]. It has been proposed that the

common trimeric architecture of TNF family ligands together with the promiscuous binding of

receptors to different ligands creates the possibility of the formation of deleterious mixed trimers

[72]. TNF mediated signaling being involved in a variety of processes ranging from cell

proliferation to cell death induction, the formation of deleterious mixed-trimers put forth a

challenge that how the receptors avoid the formation of mixed trimers to generate robust signaling?

This raises the question of whether there exists any pre-liganded assembly of TNFR1 that can

segregate specific TNF receptors prior to the ligand-binding and avoid mixed trimeric assembly

of ligand and receptors?

The crystal structure of TNFR1(PDB-1NCF)[73], reveals parallel dimeric association with

predominant interactions located on the N-terminal CRD1 **(Fig. 7A).** Consistent with this

observation, based on the

mutational studies on the

CRD1 and based on complete

replacement/exchange of this

domain with the

corresponding domain from

the related receptor, it has

been proposed that CRD1 is

responsible for ligand-

independent assembly of the

receptor, and hence named as

**Fig.7 Different dimeric interactions observed in the crystal structure of TNFR1 (A)** Parallel dimeric association of TNFR1 (PDB entry: 1NCF) interacting via the N-terminal PLAD (encircled in red dashed lines) exposes the ligand binding surface (residues shown as blue spheres). **(B)** The anti-parallel association, also observed in the same crystal structure effectively hides the ligand binding residues in the dimeric interface.

'pre-ligand binding assembly domain (PLAD)'[74]. In brief, what is evident from various studies

is that in the TNF family, the control of the signaling event is overly complex and is not mediated

by mere ligand-receptor interactions. This further supports the possibility of the existence of a pre-

signaling assembly of specific TNF receptors, prior to the ligand-binding and which is distinct

from the ligand-induced trimer. The PLAD mediated cheek-to-cheek association of TNFR1

appears to satisfy the condition required for stabilization of the 'upright' orientation of this receptor

on the cell surface. However, the existence of a long EJ-linker in TNFR1 (15 residues) raises the

question that how such a long linker stabilizes the 'upright' parallel orientation of TNFR1 on the

cell surface (TNFR2 has 56 residue EJ-linker)?

From the TNFR1 crystal structure, Naismith *et. al*, also recognize an association that can be

assigned as an anti-parallel association of the receptors, which buries the ligand biding surface

distributed over both CRD2 and CRD3 domains **(Fig. 7B).** Based on this observation, they propose

that the burial of ligand-binding residues might avoid unintended signaling events[73]. The anti-

parallel model is also convincing as it explained the differential cross-linking effects of therapeutic

agonistic and antagonistic antibodies[75]. However, the anti-parallel model undermines the role

of PLAD which was proven to be physiologically important by many experimental studies. Our

packing analysis reveals an interesting observation, where PLAD mediated parallel-dimers

associate with each other burying the ligand-binding site and forms supramolecular 1D array

containing both parallel and anti-parallel dimers **(Fig. 8).** Such an ordered and continuous

association of molecules, together with the long EJ-linker might help these molecules to stand

'upright' and segregate on the cell surface. Further, the zipper like arrangement with hidden active

sites might only respond to the presence of sufficient concentration of specific TNF ligands that

probably unzips the 1D array. Again, this observation reconciles two contradicting experimental

observations that (1) PLAD mediated parallel dimerization is important for function and (2) anti-

parallel association is physiologically relevant. Further, the 1D zipper mediated segregation of

specific kinds of TNFRs might also avoid the deleterious mixed-trimer formation of ligands and

receptors. Supporting this observation, another crystal structure of TNFR family member called

DCR3 maintains both parallel and anti-parallel dimeric association (PDB-3MHD) **(Fig S8)**,

probably suggesting a common association preference of TNFR family members. The role of

transmembrane domain of the TNF receptors in stabilisation of ligand induced trimeric association

is discussed in the **supplementary information- section 5.** Hence, signatures at the TM domain

that support the trimerization and those at the ectodomain that supports dimerization, being facile,

appear to facilitate the required oligomeric organization depending on the pre- and post signaling
states.

Recently, various inhibitors are designed to manipulate the PLAD assembly and have been shown
to inhibit downstream signaling [76][77][78], suggesting the existence of PLAD assembly on the
cell membrane. Further, hereditary heterozygous mutations in the Fas receptor, which also belongs
to the TNFR1 family (explained in the main text), exhibit a dominant-negative effect leading to
Autoimmune lymphoproliferative syndrome (ALPS).  In patients with ALPS disease, the mutant
Fas receptors cannot bind to the Fas ligand. But, since they are heterozygous mutants, when co-
expressed along with wild type(wt) receptors, the non- ligand binding mutant Fas receptors were
found to interfere in the apoptosis activity
of wt receptors indicating that the mutant
receptors can interact with the wt
receptors even prior to the ligand-induced
trimerization[72]. These observations
indicate the *cis* interaction of the Fas
receptors on the cell surface.

Apart from the specific examples
described above, the mode of association
of several cell surface receptors observed
in the crystal structures mimic the
condition required for stable 'upright'
orientation. One of the classic examples
that clearly depicts the importance of
crystallographically observed *cis*-
association of TIGIT that was later proven
to be important for signalling is also
discussed. (**supplementary information**
**- section 6 and Fig. S6**).

**Fig.8** One dimensional array observed in the crystal structure of TNFR1 that supports both parallel and antiparallel dimeric associations. Such an array of molecules on the cell membrane stabilized by velcro of weak interactions support the upright orientation of receptors and accounts for the importance of PLAD (encircled in red dashes) in receptor association as well as hides the ligand binding site (spheres in blue) to prevent spurious signalling and thus reconciles the opposing views.

Our analysis also suggests that
stabilization of 'upright' orientation can be mediated by any part of the ectodomain, and appears

to be optimally carved for its size, architecture, and functional role. Adding to these possibilities,
small molecules and ions in the extracellular milieu can also contribute to the specific organization
of cell surface proteins. Similarly, the negative charge on glycans is expected to repel from the
membrane and probably help the weakly associated molecules to stand 'upright'[79] **(See,**
**supplementary information- section 7&8)**

**Conclusion:**

Spontaneous organization is a general phenomenon observed at all length scales [80, 81]and is
fundamental to all living cells, where their shapes, motility and functions are controlled by protein
assemblies. Even the cell surface is compartmentalized to exert versatile and robust function. Here,
we observe that the cell-surface molecules oligomerize to support appropriate positioning of the
membrane distal domains for robust signaling, effectively avoiding spurious signaling events.
More interestingly, the *cis*-association of these molecules coherently reconcile contradicting
observations suggesting that the oligomerization and often formation of an ordered array is a
common phenomenon, probably utilized by many (if not all) of the cell surface molecules involved
in signaling. However, none of these proteins show such oligomerization propensity in solution,
suggesting that the observed *cis*-interactions are too weak-to-be-detected by biophysical studies.
This weak oligomerization propensity appears to be essential as these molecules are required to
organize/reorganize depending on the signaling state. Supporting this observation, as discussed
earlier, the mutation studies to understand these interactions as well as those mutations associated
with pathological conditions resulted in impaired signaling. The analysis and the conclusions
drawn here entirely relies on the repeatability of a pattern, i.e., the pattern of association in several
crystal structures of the same or related molecules, and repeated observation that constitutively
expressed cell-surface molecules oligomerize and often bury their ligand-binding surface and so
on. To retrieve a pattern and matching them requires sufficient structural and functional data on
these molecules to efficiently connect the results of the pattern of association to their functional
roles. For example, pMHCII and TCR are molecules involved in the continuous screening process;
hence, the self-association of pMHCII into higher-ordered arrays may not support efficient peptide
presentation. Similarly, the pMHCII recognition site on TCR should always be accessible.
Accordingly, neither the pMHCII superdimer nor the TCR gets involved in a supramolecular
organization. Since, the antigenic peptide already provides required specificity between TCR and

pMHCII, an additional restriction may not be required.  In contrast to specific TCR:pMHCII
interaction, the binding of CD4:pMHCII is non-specific. Accordingly, CD4 function is regulated
by its *cis*-oligomerization as well as by the formation of pre-liganded 1D array, which hides its
pMHCII biding surface in the non-signaling resting state. Hence, CD4 interacts with pMHCII only
upon proper recognition of antigenic peptide by TCR that opens the CD4 binding site on pMHCII.
In the case of TNFR1, a constitutively expressed protein, the observed 1D array suffice the
requirements for both the contradicting observations as well avoids spurious signaling. Hence, it
appears that these signaling molecules are carved with well-defined surface chemistry and
complementarity, the strength of which appears to be optimal for their functional role. Therefore,
what is generally termed as cluster of molecules on the cell surface, without any impetus to their
specific order, appears to be inappropriate and models such as 'lipid-rafts' and even the 'fence and
pickets' may not provide an explanation that emulates specific sorting and robust signaling ability
of these molecules. Although thousands of experimental work supporting these models co-exist
with unhealthy controversies[14], in the absence of know-how on their ordered association
preferences, more experiments and controversies continue to spring. It can be arguable that the
observed effect of 'lipid-rafts' or 'fences and pickets' or 'molecular crowding' is probably a
consequence of the inherent ordered association of cell surface proteins that places their relatively
rigid transmembrane domain in regular and ordered fashion to which molecules such as
sphingolipids and cholesterol can adhere to.

Similarly, as observed in the crystal structures of hCD2, cadherins, ephrin and so on, when these
molecules are free in solution, at higher concentrations they can form large arrays of the dimension
of the crystal itself (~100 microns). In contrast, when they are tethered to a membrane, the
dynamics of cytoskeleton supported active membrane might limit the growth of these weakly
associated arrays or due to the curved membrane architecture. Hence, it appears that 'fences and
pickets' imagined out of cytoskeleton elements, probably can control the growth of these clusters,
but may not carry an element of their organization specificity and functional control. Consonant
with this observation, recent studies demonstrate that when the cytoskeleton is disturbed by
cytoskeleton inhibitor 'latrunculin A', cadherin clusters were found to grow to a size that is larger
than generally observed [82].

Overall, it appears that the clustering being the key element of signal processing; the rules that

govern the clustering, their type, optimum strength, accuracy and reproducibility of the signal are

hidden within the defined set of self-organizations of cell surface molecules. Such an organization

is maintained by surface complementarity of the molecules together with polar interactions that

are facile enough to allow their organization/reorganization depending on the functional context.

The role of much neglected EJ-linker in *cis*-association of these molecules is also described here,

suggesting elements of weak association can be located anywhere on the intracellular, TM and

extracellular part of the molecule or cumulative effect of all these interactions. The presence of

cognate-partner with higher affinity and appropriate concentration might dislodge the pre-liganded

*cis*-interactions and reorganize into an array of different architecture, strength and dimension and

consequently position their intracellular cytoplasmic domains in an ordered fashion, the altered

geometry of which might support the recruitment of downstream signaling molecules. Considering

these observations, we would like to call our model as "Preferential Protein Interaction of

Signaling Receptors" (**PPISR-Model**). In the absence of a suitable model that can explain the cell

surface heterogeneity and its importance in function, we believe that this new conceptual

framework solely developed based on the available data and recurrence of pattern, appears to

provide a basis for future experiments for molecules not only involved in immune function but

also for a repertoire of other signaling receptors. Further, the knowledge of the physiological

association of the cell surface receptors in their resting state is very important to understand the

signalling mechanism and also in the light of drug design. Mostly, the inhibitory antibodies are

designed for blocking the active sites of the receptor to preclude its binding to the cognate partner.

If the observed *cis*-association in which the binding site is buried is true, then the inclusion of this

knowledge in drug design will be more effective. This is exemplified in the case of TNFR2

receptors by the requirement of at least a $F(ab)_2$ antibody rather than a single Fab fragment to

effectively lock the physiological confirmation and render antagonism[75, 83]. Further, such an

understanding will form the basis for the design of drugs that disturb or stabilize the weak pre-

liganded assembly.

**Acknowledgment**

UAR would like to thank DBT, India for Ramalingaswamy fellowship (2011-2015) and Vision

Group on Science and Technology (VGST), grant #191, Karnataka, India. SL would like to

acknowledge the fellowship from CSIR, Government of India. The authors would like to

acknowledge Admar Mutt Education Foundation (AMEF) for the facility and support.

**Author contribution**

UAR conceptualized and reviewed the manuscript. UAR and SL analysed the data and wrote the

manuscript

**Declaration of Interest**

Authors declare no conflict of interest

**Supplementary Materials:**

Methodology

Figures S1- S10

**References:**

1.   Alberts B, J.A., Lewis J, et al., *Membrane Proteins*, in *Molecular Biology of the Cell*. 2008,
Garland Science: NewYork.

2.   Garcia-Parajo, M.F., et al., *Nanoclustering as a dominant feature of plasma membrane*
*organization.* J Cell Sci, 2014. **127**(Pt 23): p. 4995-5005.

3.   Recouvreux, P. and P.F. Lenne, *Molecular clustering in the cell: from weak interactions*
*to optimized functional architectures.* Curr Opin Cell Biol, 2016. **38**: p. 18-23.

4.   Liu, W., H. Wang, and C. Xu, *Antigen Receptor Nanoclusters: Small Units with Big*
*Functions.* Trends Immunol, 2016. **37**(10): p. 680-689.

5.   Hartman, N.C. and J.T. Groves, *Signaling clusters in the cell membrane.* Curr Opin Cell
Biol, 2011. **23**(4): p. 370-6.

6.   Simons, K. and E. Ikonen, *Functional rafts in cell membranes.* Nature, 1997. **387**(6633):
p. 569-72.

7.   Lowe, M., et al., *The more the merrier: effects of macromolecular crowding on the*
*structure and dynamics of biological membranes.* FEBS J, 2020. **287**(23): p. 5039-5067.

8.   Kusumi, A., et al., *Paradigm shift of the plasma membrane concept from the two-*
*dimensional continuum fluid to the partitioned fluid: high-speed single-molecule tracking*
*of membrane molecules.* Annu Rev Biophys Biomol Struct, 2005. **34**: p. 351-78.

9.   Sieber, J.J., et al., *Anatomy and dynamics of a supramolecular membrane protein cluster.*
Science, 2007. **317**(5841): p. 1072-6.

10.    Levental, I. and S. Veatch, *The Continuing Mystery of Lipid Rafts.* J Mol Biol, 2016.
**428**(24 Pt A): p. 4749-4764.
11.    Sevcsik, E. and G.J. Schutz, *With or without rafts? Alternative views on cell membranes.*
Bioessays, 2016. **38**(2): p. 129-39.
12.    Nichols, B., *Cell biology: without a raft.* Nature, 2005. **436**(7051): p. 638-9.
13.    Calder, P.C. and P. Yaqoob, *Lipid rafts--composition, characterization, and controversies.*
J Nutr, 2007. **137**(3): p. 545-7.
14.    Levental, I., K.R. Levental, and F.A. Heberle, *Lipid Rafts: Controversies Resolved,*
*Mysteries Remain.* Trends Cell Biol, 2020. **30**(5): p. 341-353.
15.    Bernardino de la Serna, J., et al., *There Is No Simple Model of the Plasma Membrane*
*Organization.* Front Cell Dev Biol, 2016. **4**: p. 106.
16.    Low, S.H., et al., *Syntaxins 3 and 4 are concentrated in separate clusters on the plasma*
*membrane before the establishment of cell polarity.* Mol Biol Cell, 2006. **17**(2): p. 977-89.
17.    Uhles, S., et al., *Isoform-specific insulin receptor signaling involves different plasma*
*membrane domains.* J Cell Biol, 2003. **163**(6): p. 1327-37.
18.    Magenau, A., et al., *Discreet and distinct clustering of five model membrane proteins*
*revealed by single molecule localization microscopy.* Mol Membr Biol, 2015. **32**(1): p. 11-
8.
19.    Vyas, N., et al., *Nanoscale organization of hedgehog is essential for long-range signaling.*
Cell, 2008. **133**(7): p. 1214-27.
20.    Davis, S.J. and P.A. van der Merwe, *The kinetic-segregation model: TCR triggering and*
*beyond.* Nat Immunol, 2006. **7**(8): p. 803-9.
21.    Truong-Quang, B.A. and P.F. Lenne, *Membrane microdomains: from seeing to*
*understanding.* Front Plant Sci, 2014. **5**: p. 18.
22.    Liu, C., et al., *Single-Molecule Tracking and Its Application in Biomolecular Binding*
*Detection.* IEEE J Sel Top Quantum Electron, 2016. **22**(4).
23.    Sibarita, J.B., *High-density single-particle tracking: quantifying molecule organization*
*and dynamics at the nanoscale.* Histochem Cell Biol, 2014. **141**(6): p. 587-95.
24.    Siegel, R.M., et al., *Measurement of molecular interactions in living cells by fluorescence*
*resonance energy transfer between variants of the green fluorescent protein.* Sci STKE,
2000. **2000**(38): p. pl1.
25.    Baaden, M., *Visualizing Biological Membrane Organization and Dynamics.* J Mol Biol,
2019. **431**(10): p. 1889-1919.
26.    Honig, B. and L. Shapiro, *Adhesion Protein Structure, Molecular Affinities, and Principles*
*of Cell-Cell Recognition.* Cell, 2020. **181**(3): p. 520-535.
27.    Price, W.N., 2nd, et al., *Understanding the physical properties that control protein*
*crystallization by analysis of large-scale experimental data.* Nat Biotechnol, 2009. **27**(1):
p. 51-7.
28.    Ikemizu, S., et al., *Structure and dimerization of a soluble form of B7-1.* Immunity, 2000.
**12**(1): p. 51-60.
29.    Chen, Y., et al., *A dimeric structure of PD-L1: functional units or evolutionary relics?*
Protein Cell, 2010. **1**(2): p. 153-60.
30.    Cao, E., et al., *NTB-A receptor crystal structure: insights into homophilic interactions in*
*the signaling lymphocytic activation molecule receptor family.* Immunity, 2006. **25**(4): p.
559-70.

31.   Bodian, D.L., et al., *Crystal structure of the extracellular region of the human cell adhesion*
*molecule CD2 at 2.5 A resolution.* Structure, 1994. **2**(8): p. 755-66.
32.   Zhang, N., et al., *Binding of herpes simplex virus glycoprotein D to nectin-1 exploits host*
*cell adhesion.* Nat Commun, 2011. **2**: p. 577.
33.   Harrison, O.J., et al., *Nectin ectodomain structures reveal a canonical adhesive interface.*
Nat Struct Mol Biol, 2012. **19**(9): p. 906-15.
34.   Wu, H., P.D. Kwong, and W.A. Hendrickson, *Dimeric association and segmental*
*variability in the structure of human CD4.* Nature, 1997. **387**(6632): p. 527-30.
35.   Himanen, J.P., et al., *Architecture of Eph receptor clusters.* Proc Natl Acad Sci U S A,
2010. **107**(24): p. 10860-5.
36.   Chang, V.T., et al., *Initiation of T cell signaling by CD45 segregation at 'close contacts'.*
Nat Immunol, 2016. **17**(5): p. 574-582.
37.   Harrison, O.J., et al., *The extracellular architecture of adherens junctions revealed by*
*crystal structures of type I cadherins.* Structure, 2011. **19**(2): p. 244-56.
38.   Ereno-Orbea, J., et al., *Molecular basis of human CD22 function and therapeutic targeting.*
Nat Commun, 2017. **8**(1): p. 764.
39.   Kim, S.A., et al., *Calcium-dependent dynamics of cadherin interactions at cell-cell*
*junctions.* Proc Natl Acad Sci U S A, 2011. **108**(24): p. 9857-62.
40.   Klaile, E., et al., *The CEACAM1 N-terminal Ig domain mediates cis- and trans-binding*
*and is essential for allosteric rearrangements of CEACAM1 microclusters.* J Cell Biol,
2009. **187**(4): p. 553-67.
41.   Zilly, F.E., et al., *Ca2+ induces clustering of membrane proteins in the plasma membrane*
*via electrostatic interactions.* EMBO J, 2011. **30**(7): p. 1209-20.
42.   Shen, J., et al., *Extracellular Juxtamembrane Motif Critical for TrkB Preformed Dimer and*
*Activation.* Cells, 2019. **8**(8).
43.   Franco, M.L., et al., *Structural basis of the transmembrane domain dimerization and*
*rotation in the activation mechanism of the TRKA receptor by nerve growth factor.* J Biol
Chem, 2020. **295**(1): p. 275-286.
44.   He, L. and K. Hristova, *Consequences of replacing EGFR juxtamembrane domain with an*
*unstructured sequence.* Sci Rep, 2012. **2**: p. 854.
45.   Schwartz, J.C., et al., *Structural basis for co-stimulation by the human CTLA-4/B7-2*
*complex.* Nature, 2001. **410**(6828): p. 604-8.
46.   Yu, C., et al., *Rigid-body ligand recognition drives cytotoxic T-lymphocyte antigen 4*
*(CTLA-4) receptor triggering.* J Biol Chem, 2011. **286**(8): p. 6685-6696.
47.   Rudd, C.E., et al., *Molecular analysis of the interaction of p56lck with the CD4 and CD8*
*antigens.* Adv Exp Med Biol, 1991. **292**: p. 85-96.
48.   Wang, J.H., et al., *Crystal structure of the human CD4 N-terminal two-domain fragment*
*complexed to a class II MHC molecule.* Proc Natl Acad Sci U S A, 2001. **98**(19): p. 10799-
804.
49.   Kwong, P.D., et al., *Molecular characteristics of recombinant human CD4 as deduced*
*from polymorphic crystals.* Proc Natl Acad Sci U S A, 1990. **87**(16): p. 6423-7.
50.   Moldovan, M.C., et al., *CD4 dimers constitute the functional component required for T*
*cell activation.* J Immunol, 2002. **169**(11): p. 6261-8.
51.   Briant, L., et al., *Transduction of activation signal that follows HIV-1 binding to CD4 and*
*CD4 dimerization involves the immunoglobulin CDR3-like region in domain 1 of CD4.* J
Biol Chem, 1997. **272**(31): p. 19441-50.

52.     Bourgeois, R., et al., *Association between disruption of CD4 receptor dimerization and*
701              *increased human immunodeficiency virus type 1 entry.* Retrovirology, 2006. **3**: p. 31.
702     53.     Langedijk, J.P., et al., *Location of CD4 dimerization site explains critical role of CDR3-*
703              *like region in HIV-1 infection and T-cell activation and implies a model for complex of*
704              *coreceptor-MHC.* J Biol Chem, 1993. **268**(23): p. 16875-8.
705     54.     Yin, Y., X.X. Wang, and R.A. Mariuzza, *Crystal structure of a complete ternary complex*
706              *of T-cell receptor, peptide-MHC, and CD4.* Proc Natl Acad Sci U S A, 2012. **109**(14): p.
707              5405-10.
708     55.     Brown, J.H., et al., *Three-dimensional structure of the human class II histocompatibility*
709              *antigen HLA-DR1.* Nature, 1993. **364**(6432): p. 33-9.
710     56.     Gorga, J.C., et al., *Crystallization of HLA-DR antigens.* Res Immunol, 1991. **142**(5-6): p.
711              401-7.
712     57.     Stern, L.J. and D.C. Wiley, *The human class II MHC protein HLA-DR1 assembles as empty*
713              *alpha beta heterodimers in the absence of antigenic peptide.* Cell, 1992. **68**(3): p. 465-77.
714     58.     Schafer, P.H., et al., *The assembly and stability of MHC class II-(alpha beta)2 superdimers.*
715              J Immunol, 1998. **161**(5): p. 2307-16.
716     59.     Schafer, P.H., S.K. Pierce, and T.S. Jardetzky, *The structure of MHC class II: a role for*
717              *dimer of dimers.* Semin Immunol, 1995. **7**(6): p. 389-98.
718     60.     Jones, E.Y., et al., *Crystal structure at 2.8 A resolution of a soluble form of the cell*
719              *adhesion molecule CD2.* Nature, 1992. **360**(6401): p. 232-9.
720     61.     Selvaraj, P., et al., *The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-*
721              *3.* Nature, 1987. **326**(6111): p. 400-3.
722     62.     Kato, K., et al., *CD48 is a counter-receptor for mouse CD2 and is involved in T cell*
723              *activation.* J Exp Med, 1992. **176**(5): p. 1241-9.
724     63.     van der Merwe, P.A., et al., *Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with*
725              *a very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59.*
726              Biochemistry, 1994. **33**(33): p. 10149-60.
727     64.     Van der Merwe, P.A., et al., *Measuring very low affinity interactions between*
728              *immunoglobulin superfamily cell-adhesion molecules.* Biochem Soc Trans, 1993. **21**(4): p.
729              340S.
730     65.     Kundapura, S.V. and U.A. Ramagopal, *The CC' loop of IgV domains of the immune*
731              *checkpoint receptors, plays a key role in receptor:ligand affinity modulation.* Sci Rep,
732              2019. **9**(1): p. 19191.
733     66.     Staunton, D.E., et al., *Blast-1 possesses a glycosyl-phosphatidylinositol (GPI) membrane*
734              *anchor, is related to LFA-3 and OX-45, and maps to chromosome 1q21-23.* J Exp Med,
735              1989. **169**(3): p. 1087-99.
736     67.     Wong, Y.W., et al., *Structure, expression, and genetic linkage of the mouse BCM1 (OX45*
737              *or Blast-1) antigen. Evidence for genetic duplication giving rise to the BCM1 region on*
738              *mouse chromosome 1 and the CD2/LFA3 region on mouse chromosome 3.* J Exp Med,
739              1990. **171**(6): p. 2115-30.
740     68.     Murray, A.J., et al., *One sequence, two folds: a metastable structure of CD2.* Proc Natl
741              Acad Sci U S A, 1995. **92**(16): p. 7337-41.
742     69.     Douglass, A.D. and R.D. Vale, *Single-molecule microscopy reveals plasma membrane*
743              *microdomains created by protein-protein networks that exclude or trap signaling*
744              *molecules in T cells.* Cell, 2005. **121**(6): p. 937-50.

70.  Locksley, R.M., N. Killeen, and M.J. Lenardo, *The TNF and TNF receptor superfamilies:*
*integrating mammalian biology.* Cell, 2001. **104**(4): p. 487-501.
71.  Smith, C.A., T. Farrah, and R.G. Goodwin, *The TNF receptor superfamily of cellular and*
*viral proteins: activation, costimulation, and death.* Cell, 1994. **76**(6): p. 959-62.
72.  Chan, F.K., *The pre-ligand binding assembly domain: a potential target of inhibition of*
*tumour necrosis factor receptor function.* Ann Rheum Dis, 2000. **59 Suppl 1**: p. i50-3.
73.  Naismith, J.H., et al., *Crystallographic evidence for dimerization of unliganded tumor*
*necrosis factor receptor.* J Biol Chem, 1995. **270**(22): p. 13303-7.
74.  Chan, F.K., et al., *A domain in TNF receptors that mediates ligand-independent receptor*
*assembly and signaling.* Science, 2000. **288**(5475): p. 2351-4.
75.  Vanamee, E.S. and D.L. Faustman, *Structural principles of tumor necrosis factor*
*superfamily signaling.* Sci Signal, 2018. **11**(511).
76.  Deng, G.M., *Tumor necrosis factor receptor pre-ligand assembly domain is an important*
*therapeutic target in inflammatory arthritis.* BioDrugs, 2007. **21**(1): p. 23-9.
77.  Lo, C.H., et al., *Noncompetitive inhibitors of TNFR1 probe conformational activation*
*states.* Sci Signal, 2019. **12**(592).
78.  O'Connell, J., et al., *Small molecules that inhibit TNF signalling by stabilising an*
*asymmetric form of the trimer.* Nat Commun, 2019. **10**(1): p. 5795.
79.  Polley, A., et al., *Glycosylation and Lipids Working in Concert Direct CD2 Ectodomain*
*Orientation and Presentation.* J Phys Chem Lett, 2017. **8**(5): p. 1060-1066.
80.  Weirich, K.L., et al., *Self-organizing motors divide active liquid droplets.* Proc Natl Acad
Sci U S A, 2019. **116**(23): p. 11125-11130.
81.  Karsenti, E., *Self-organization in cell biology: a brief history.* Nat Rev Mol Cell Biol, 2008.
**9**(3): p. 255-62.
82.  Wu, Y., P. Kanchanawong, and R. Zaidel-Bar, *Actin-delimited adhesion-independent*
*clustering of E-cadherin forms the nanoscale building blocks of adherens junctions.* Dev
Cell, 2015. **32**(2): p. 139-54.
83.  Torrey, H., et al., *Targeting TNFR2 with antagonistic antibodies inhibits proliferation of*
*ovarian cancer cells and tumor-associated Tregs.* Sci Signal, 2017. **10**(462).